IPF Life Expectancy in 2026: What the Statistics Don’t Tell You

If you or someone you love has just been diagnosed with idiopathic pulmonary fibrosis, there is a good chance the first statistic you encountered was brutal: a median survival of 3 to 5 years. We are not going to pretend that number does not exist — because it does, and it matters, and anyone living with IPF deserves honesty about what they are facing.

But here is what that number does not tell you: it was calculated largely before the treatments we now have were widely available. And the story of IPF in 2025 and beyond looks meaningfully different.

This article starts with the hard truth — and then takes you somewhere more hopeful, because the science has earned it.

“One of the hardest conversations we have with IPF patients is around the statistics they’ve read online. What I try to help them understand is that those numbers come from an era before the treatments we have now. The research is moving fast — and our job at QuickRx is to make sure cost is never the reason someone can’t access the medications that are giving people more time.”

Julia Kravtsova, PharmD, Head Patient Navigator at QuickRx Specialty Pharmacy

The reality of an IPF diagnosis — what the numbers say

Idiopathic pulmonary fibrosis is a progressive, chronic lung disease in which scar tissue — fibrosis — forms in the lungs, gradually replacing healthy tissue and making breathing harder over time. The word “idiopathic” means the exact cause remains unknown, which makes it both difficult to prevent and difficult to treat.

The statistics are sobering — but they belong to an era that is already changing.

Sources: AJRCCM 2011 · CDC MMWR 2025 · Medscape IPF Overview

These numbers are real, and patients and caregivers deserve to understand them. But they are also, increasingly, the numbers of a different era of IPF care — one that existed before two FDA-approved antifibrotic medications fundamentally changed the disease trajectory for hundreds of thousands of patients worldwide.

Why those statistics are already becoming outdated

The frequently cited 3–5 year survival estimate originates from studies conducted largely before 2014 — the year both OFEV (nintedanib) and Esbriet (pirfenidone) received FDA approval as the first-ever treatments shown to slow the progression of IPF.

Before 2014, there was no approved treatment that meaningfully altered the disease course. The statistics reflected a disease in an era of best supportive care only — symptom management, oxygen, pulmonary rehabilitation — without anything capable of reducing the rate of lung scarring itself.

Real-world data published in the American Journal of Managed Care now shows that antifibrotic therapy use is associated with improvement in life expectancy in real-world IPF populations — not just in tightly controlled clinical trials. Lung transplantation — now increasingly performed for IPF patients — offers approximately 89% 1-year survival and 74% 3-year survival for those who qualify.

The course of IPF still varies widely. Some patients experience rapid progression. Others remain relatively stable for years. No medication currently available cures IPF or reverses existing scarring. But the trajectory of what is possible has shifted — and it continues to shift.

OFEV — still the gold standard, still the most accessible option today

OFEV (nintedanib) remains the most prescribed, most studied, and most accessible first-line treatment for IPF in 2026. Manufactured by Boehringer Ingelheim and FDA-approved in October 2014, it now has over a decade of real-world safety and efficacy data behind it — along with robust copay assistance programs that make it affordable for most commercially insured patients. While newer medications are exciting, OFEV is what is available, proven, and accessible right now. The evidence behind it is some of the most important data in the history of this disease.

In the landmark INPULSIS-1 and INPULSIS-2 clinical trials, published in the New England Journal of Medicine, nintedanib reduced the annual rate of forced vital capacity (FVC) decline — the primary measure of lung function loss — by approximately 50% compared to placebo. The chart below shows what that means in real numbers.

In INPULSIS-2, nintedanib also significantly reduced the risk of acute exacerbations. Long-term extension data confirmed that this benefit persisted for up to three years of continuous treatment, and a combined analysis shows a trend toward reduced mortality.

A separate analysis published in the Journal of Managed Care & Specialty Pharmacy found that pirfenidone (Esbriet) improved mean life expectancy by approximately 2.47 years compared to best supportive care alone. The chart below puts that in perspective.

“OFEV doesn’t cure IPF — but it gives people more time. And more time matters enormously. Making sure every eligible patient can actually access and afford nintedanib is something we take personally at QuickRx.”

Julia Kravtsova, PharmD, Head Patient Navigator at QuickRx Specialty Pharmacy

The first new IPF treatment in over a decade — approved October 2025

For eleven years after the approval of nintedanib and pirfenidone, the IPF treatment landscape remained unchanged. Then, on October 7, 2025, the FDA approved Jascayd (nerandomilast) — the first new IPF treatment in over a decade.

Nerandomilast is a first-in-class, oral, preferential inhibitor of phosphodiesterase 4B (PDE4B). Its mechanism of action is distinct from both OFEV and Esbriet — working through both immunomodulatory and antifibrotic pathways. The FDA granted it both Priority Review and Breakthrough Therapy Designation.

The approval followed the FIBRONEER-IPF Phase III trial, published in the New England Journal of Medicine in May 2025. More than 2,200 patients in over 40 countries participated. Participants on nerandomilast saw significantly less FVC decline compared to placebo — and crucially, the drug worked both as a standalone therapy and alongside existing treatments like nintedanib.

Action for Pulmonary Fibrosis called the results “a breakthrough we can actually see” — marking a turning point after more than a decade without new options.

What is coming next — the research pipeline

The approval of nerandomilast marks the beginning of what may be the most active and promising period in IPF drug development ever recorded. According to a 2024 pipeline analysis published in AJMC, more than 80 companies worldwide are developing more than 100 therapies for IPF — spanning preclinical through Phase III.

Notable developments include United Therapeutics’ inhaled treprostinil (Tyvaso), which posted positive Phase III TETON-2 results in September 2025. The Pulmonary Fibrosis Foundation called the TETON-2 results “a significant accomplishment for the drug development space and PF community.” Bristol Myers Squibb’s admilparant, an LPA1 receptor antagonist, is also in Phase III with results expected by October 2026.

The journal Expert Review of Clinical Pharmacology identified 30 experimental agents with unique mechanisms of action under evaluation for IPF in a 2024 review — a number that would have been unimaginable a decade ago.

How AI is accelerating IPF drug discovery

Perhaps the most unexpected development in IPF research is the role that artificial intelligence is beginning to play — and it is genuinely remarkable.

In 2024, results appeared in Nature Medicine from the first Phase 2a trial of a drug entirely discovered and designed by generative AI. The drug, rentosertib, developed by Insilico Medicine, targets TNIK — a kinase in fibrotic pathways that human researchers had not previously identified as an IPF drug target. The AI platform found it by integrating genomics, transcriptomics, and proteomics data simultaneously — a task that would have taken human researchers years to analyze manually.

The Phase 2a trial enrolled 71 patients at 21 sites in China. Results showed the drug was safe with early efficacy signals. A global Phase IIb study is now in planning.

This matters because AI does not just speed up drug development — it finds entirely new doors. Every novel mechanism of action identified represents a potential path to therapies that work differently, work better, or work for patients who do not respond to current options.

Sources: AJMC 2024 pipeline report · Boehringer Ingelheim · Nature Medicine 2025

References

1. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440. atsjournals.org
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. nejm.org
3. Fisher M, Nathan SD, Hill C, et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2017;23(3-b):S17–S24. jmcp.org
4. Richeldi L, Azuma A, Cottin V, et al. Trial of a preferential phosphodiesterase 4B inhibitor for IPF (FIBRONEER-IPF). N Engl J Med. 2025;392:2193–2202. nejm.org
5. Boehringer Ingelheim. FDA approves Jascayd (nerandomilast) for IPF. October 9, 2025. boehringer-ingelheim.com
6. Action for Pulmonary Fibrosis. Landmark clinical trial offers new hope. May 19, 2025. actionpf.org
7. Pulmonary Fibrosis Foundation. October 2025 clinical trial highlights. pulmonaryfibrosis.org
8. Ren F, et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine. 2025. nature.com
9. Aribindi K, Liu GY, Albertson TE. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis. Expert Rev Clin Pharmacol. 2024;17(9):817–835. PMC11441789
10. AJMC. Real-world data on the course of idiopathic pulmonary fibrosis. ajmc.com
11. CDC. Idiopathic pulmonary fibrosis mortality by industry and occupation. MMWR. 2025;74(7). cdc.gov
12. Action for Pulmonary Fibrosis. Pulmonary fibrosis life expectancy. actionpf.org
13. AJMC. Report highlights advancements in 2024 IPF pipeline. ajmc.com